this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
10.1016/j.neuropharm.2019.107777 390 ZhangT.MishraP.HayB
This was followed by a reduced maintenance dose of 25 mg/kg, administered three times weekly until the third month
New product training (what-what!!)
When paired with endotoxin-free peptides , bacteriostatic water helps maintain solution integrity during multi-use laboratory workflows, provided endotoxin-controlled handling and storage protocols are followed
2012;81(4):3708 Hopf M, Kloos C, Wolf G, Muller UA, Muller N
